The business is known by its full name, Global Blood Therapeutics, Inc. (NASDAQ: GBT). On September 21st, the research analysts at Cantor Fitzgerald shared their forecasts for the earnings per share (EPS) that Global Blood Therapeutics will bring in during the fiscal year 2022. Cantor Fitzgerald predicted the company would earn $4.55 per share in profits this year. The stock currently has a rating of “Neutral” from Cantor Fitzgerald, which is the security’s rating. According to the consensus estimate, the current profit forecast for Global Blood Therapeutics’ full year is expected to come in at $4.71 per share. This projection was derived from the company’s financial statements. In addition, the analysts at Cantor Fitzgerald anticipated that Global Blood Therapeutics’ earnings would come in at $3.03 per share for the upcoming fiscal year 2023.
Other analysts have only recently published their reports on the company under discussion. Global Blood Therapeutics was downgraded by Wells Fargo & Company from “overweight” to “equal weight” in a research note published on the 9th of August. In addition, they increased the price target from $66.00 to $68.50. Guggenheim stated they would be increasing their price objective for Global Blood Therapeutics to $72.00 in a research report published on Monday, August 15th. In a research study that was made public on the 8th of August, William Blair lowered their recommendation for Global Blood Therapeutics from “outperform” to “market perform” in a research study. Canaccord Genuity Group upgraded their recommendation for Global Blood Therapeutics to “buy” in a research report released on Monday, August 8th. It increased their price objective for the stock from $40.00 to $72.00 in a research report released on Monday, August 8th. The report was made available online. They also raised their price target for the stock to $72.00, having previously set it at $40.00. SVB Leerink has downgraded Global Blood Therapeutics, moving the company’s stock price target from “outperform” to “market perform,” but that’s not the end of the bad news. In a research note published on Tuesday, August 9th, thirteen equity research analysts suggested that investors maintain their current shares of shares of the company’s stock, while only five of these analysts recommended that investors purchase shares of the company’s stock. Bloomberg says that the overall rating for the stock is “Hold” and that most analysts polled have set the price target for the stock at $65.50.
When trading started on Friday, the price of a share of Global Blood Therapeutics was $67.97. The price-to-earnings ratio for the stock is currently at -13.57, its beta value is at 0.46, and its market capitalization is currently $4.59 billion. During the last year, the price of a share of Global Blood Therapeutics has ranged from as low as $21.65 to as high as $73.02. Over the last 50 days, the company’s simple moving average price was $57.63; over the last 200 days, it was $39.72. While the debt-to-equity ratio, the current ratio, and the quick ratio are all equal to 4.92, the other two ratios currently stand at 6.88 and 6.17, respectively.
Global Blood Therapeutics (NASDAQ: GBT) released a report detailing its most recent quarterly financial performance on Monday, August 8th. The company’s earnings per share (EPS) for the quarter came in at $1.26, which was $0.26 less than market experts’ estimate collectively, which was $1.19. In addition, the return on equity and the net margin for Global Blood Therapeutics were red. The return on equity was -170.37%, and the net margin was -137.30%. The revenue for the quarter came in significantly higher than the $64.39 million analysts had anticipated, coming in at a total of $71.55 million instead. The company incurred a loss of $1.1 per share during the same period the previous year.
As reported in the news article linked above, business insider Nazila Habibizad sold a total of 4,678 shares of company stock. The sale of the stock resulted in total revenue of $314,314.82, with the average price of each share being $67.19. As a result of the purchase, the insider now owns a total of 8,918 shares of the company, which have a value of $599,200.42. This page contains the filing containing the information about the transaction provided to the Securities and Exchange Commission (SEC). You can access the filing by clicking here. At this time, insiders hold a percentage of the company’s stock equal 4.90 percent.
Hedge funds have, in recent times, experimented with different allocations of the stock holdings contained within their portfolios. Over the first three months of this year, SkyView Investment Advisors LLC saw a rise of 587.2% in the percentage of Global Blood Therapeutics stock it owned. SkyView Investment Advisors LLC increased the number of shares of the company’s stock that it owned during the quarter by purchasing an additional 687 shares at the cost of $28,000. This brought the total number of shares that the firm owned to 804, bringing the total value of those shares to $28,000. The portfolio held by Nisa Investment Advisors LLC saw an increase of 75.6% in the number of shares of Global Blood Therapeutics over the first three months of the year. Following the acquisition of an additional 650 shares during the period in question, Nisa Investment Advisors LLC now holds 1,510 shares of the company’s stock. Each share of company stock has a current market value of $52,000. During the final three months of 2018, Advisor Group Holdings Inc. grew its ownership stake in Global Blood Therapeutics by 31.8%. After purchasing an additional 450 shares during the most recent period, Advisor Group Holdings Inc. now has 1,865 shares of the company’s stock, currently valued at $55,000. This is due to Advisor Group Holdings Inc.’s ownership of 1,865 shares of the company’s stock. During the second quarter, Quantamental Technologies LLC increased its ownership stake in Global Blood Therapeutics by almost the same amount, purchasing approximately 204,000 shares. And last but not least, during the second quarter, Wedbush Securities Inc. invested in Global Blood Therapeutics that was valued at a total of $207,000.